Ireland
--:--IST
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 35 Florida 33 Illinois 19 New York 18 Massachusetts 18
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Texas

12 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
Regor Pharmaceuticals Inc.
Phase 1
63
California, Texas, Virginia
2026-06
Active, closed
Endometrial Cancer Vaginal Fluid Specimen Collection Study
NCT07544680Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
Exact Sciences Corporation
Observational
4,200
Florida, Maine, Tennessee, Texas
2026-03-10
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor
Aadi Bioscience, Inc.
Phase 2
29
Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas
2023-12-28
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
Bio-Path Holdings, Inc.
Phase 1
50
Maryland, Michigan, Texas
2022-08-19
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Active, closed
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
USWM CT, LLC
Phase 1
120
Florida, Massachusetts, Missouri, New York, North Carolina, Oklahoma, Tennessee, Texas
2019-08-20
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

8 of the 12 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 12 studies
PhaseStudiesRecruitingShare
Phase 18666.7%
Phase 32116.7%
Observational108.3%
Phase 2118.3%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
Aadi Bioscience, Inc.11
Alterome Therapeutics, Inc.10
ArriVent BioPharma, Inc.11
Bio-Path Holdings, Inc.11
Daiichi Sankyo11
Exact Sciences Corporation10
MOMA Therapeutics11
Pfizer10
Regor Pharmaceuticals Inc.11
TORL Biotherapeutics, LLC11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.